Dalidowicz, M. What is the magnitude of risk of exposure to coronaviruses with intermediate and high risk upper GI endoscopy, ERCP and colonoscopy? 2020 Mar 31; Document no.: EOC033101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 9 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc8
Dalidowicz, M. Where and how are they producing and using intubation hoods? 2020 Mar 30; Document no.: EOC033001-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc9
Dalidowicz, M; Young, C. What is the degree of COVID-19 transmission through the administration of nebulizer medication either in clinical practice or in animal experiments? 2020 Apr 1; Document no.: EOC040101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc10
Duncan, V. Is the IgM or IgG immune response protective? 2020 Apr 8; Document no.: LAB040803-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc38
Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 14; Document no.: LAB041402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 42 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc39
Howell-Spooner, B. What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? 2020 May 8; Document no.: LAB040701v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 25 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc78
Duncan, V; Howell-Spooner, B. What is the relationship between antibody development and viral shedding and infectiousness? 2020 May 22; Document no.: LAB041601v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 30 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc93
Ellsworth, C; Fox, L. What are the safety risks or disinfection concerns with the use of intubation boxes? 2020 Sep 2; Document no.: EOC090202-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 20 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc168
Miller, L.; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 4; Document no.: EOC062201v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 46 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc232
Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 01; Document no.: EOC210302 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc289
Miller, L; Mueller, M. What are the one year outcomes for ICU COVID patients? 2022 Feb 10. Document no.: EOC220201 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 46 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc440
Dalidowicz, M; Howell-Spooner, B. What is the efficacy of a 4th booster dose for COVID-19? 2022 May 27, Document no.: EOC220304v002 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 23 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc493
Mueller, M; Dalidowicz, M. Long COVID: What does it mean for the healthcare system and programs to? 2021 Oct 21, Document no.: EOC021901v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 70 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc386
